Good morning. We start with the money and the models reshaping super intelligence, then turn to new chip capacity, safety research, and a tiny implant with a very human promise.
Anthropic told prospective investors its third quarter revenue rose about 45 percent to $16.8 billion ahead of a planned public listing. Why it matters: enterprise demand for frontier models is turning into real, large scale revenue, and a public listing would reset pricing and competition across the whole sector.
Google says its new Gemini 4 Argon model helped the Chrome team complete a major refactor of about 6 million lines of legacy code in weeks rather than months. Why it matters: Argon is being credited with work inside Google itself, at a reported cost well below rival models, a sign the race is about useful output per dollar again, not just scale.
GlobalFoundries will operate two new semiconductor fabs in Malta, New York, under a US and Japan initiative worth up to $21 billion, with the first plant expected in 2029. Why it matters: paired with ASML reporting customer interest in orders for 2029 and 2030, it shows chip capacity is being locked in years ahead to meet lasting demand.
NVIDIA will provide $250 million in computing resources over five years for AI safety research in the UK, supporting teams at Oxford, UCL, Imperial and others. Why it matters: the same compute that builds more capable agents is now being directed, in a serious way, toward testing how those agents behave and how to keep them safe.
Bengaluru startup Scimplify raised $25 million to expand its AI powered production of specialty chemicals and critical materials for chips, defense and energy. Why it matters: the company says it can move from a customer brief to a finished material in about two months instead of 12 to 18, offering manufacturers a real alternative in concentrated supply chains.
Science Corporation has implanted its PRIMA vision restoring chip in its first patient with Stargardt disease, an inherited condition that gradually destroys central vision. Why it matters: PRIMA is already available in Europe for another form of vision loss, and early rehabilitation reports of reading letters and words point to a wider future for retinal implants.
